Skip to main content
FDA Updates
Vitrakvi (Larotrectinib) First TRK Inhibitor Approved by the FDA for Solid Tumors Based on a Genetic Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
Online Only
FDA Updates
Udenyca (Pegfilgrastim-cbqv) Second Biosimilar Approved to Reduce the Incidence of Infection Associated with Febrile Neutropenia
Lisa A. Raedler, PhD, RPh, Medical Writer
Read More
Online Only
FDA Updates, Prostate Cancer
Yonsa (Fine-Particle Abiraterone Acetate) New Formulation Approved for Metastatic Prostate Cancer
Loretta Fala, Medical Writer
Read More
Breast Cancer, FDA Updates
FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer
Yvette Florio Lane
Read More
FDA Updates
Tibsovo Now FDA Approved as First-Line Treatment for AML with IDH1 Mutation
Yvette Florio Lane
Read More
Renal-Cell Carcinoma, FDA Updates
FDA Approves Pembrolizumab plus Axitinib for Advanced Renal-Cell Carcinoma
Yvette Florio Lane
Read More
Lung Cancer, FDA Updates
April 16, 2019 – FDA Approvals, News & Updates
Yvette Florio Lane
Read More
Breast Cancer, FDA Updates
FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer
Yvette Florio Lane
Read More
Breast Cancer, FDA Updates
Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness
Yvette Florio Lane
Read More
Lung Cancer, FDA Updates
FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer
Yvette Florio Lane
Read More
Page 154 of 200
Results 1531 - 1540 of 1993